louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00096837: A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Official title: An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Myeloma
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Lead sponsor: Pharmacyclics LLC.
Sponsor class: INDUSTRY
First posted: 2004-11-17
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.


Eligibility criteria: Inclusion Criteria:

* Relapsed or Refractory Multiple Myeloma
* ≥ 18 years old
* Able to provide consent for participation
* ECOG status 0-2

Lab values:

* ANC ≥ 1,000/µL
* WBC count ≥ 2.0/µL
* Hemoglobin ≥ 8.0 g/dL
* Platelet count ≥ 50,000/µL
* AST and ALT ≤ 2 x ULN
* Total Bilirubin ≤ 2 x ULN
* Creatinine ≤ 2.0 mg/dL

and

* Not pregnant or lactating

Primary outcomes:
measure: Rate of complete response, partial response and stable disease (clinical benefit rate)
Secondary outcomes:
measure: Progression-free survival
measure: Safety and tolerability
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Robert H. Lurie Comprehensive Cancer Center
state: Illinois
Study officials:
References:
Clinical trial NCT00835315: Prevalence of Psoriasis Alba in Psoriatic Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Psoriasis
Keywords: interdigital psoriasis (psoriasis alba)
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2009-02-03
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients of dermatology depatment and outpatient clinic in the hospital

Brief summary: Interdigital psoriasis (psoriasis alba) is atypical and rare form of psoriasis that is often missed as it is commonly mistaken for either dermatoses or fungal infection.In this study we observed and analyzed the prevalence of psoriasis interdigital of palms and soles and brought medical awareness to dermatologists and family doctors this rare form of psoriasis. Thus, you can help to avoid mistaken diagnosis and the start of correct treatment as soon as possible.

Detailed description: Hospitalized patients and outpatient clinic will be included in the study after receiving the signature of a inform consent.Patients groups : 100 patients with psoriasis,100 patients with atopic dermatitis and 100 healthy patients (control group).Patients with atopic dermatitis will be the secondary control group.Patients diagnosed with inflammatory condition of interdigital skin of the palms and soles will be checked by fungal microscopy test.If the fungal test is negative ,we need to prepare to a biopsy of the skin in this area .Following results of the skin biopsy conclusions can be shown about the prevalence of interdigital psoriasis in psoriatic patients enabling suitable treatment to be given to the patients.

Eligibility criteria: Inclusion Criteria:

* patients above 18 years old ,hebrew speakers, patients with psoriasis vulgaris or atopic dermatitis without systemic treatment

Exclusion Criteria:

* patients below 18 years old, pregnancy women, patients treated with systemic agents for psoriasis or atopic dermatitis(methotrexate,cyclosporin,neotigason)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hadassah Medical Organization
name: Vera Leibovici, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hadassah Medical Organization
name: Natalya Lemster, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03655015: Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Official title: Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Neoplasm
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2018-08-31
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lung cancer patients

Brief summary: Create a living biobank of PDOs from Stage I-III lung cancer patients.

Detailed description: Creation a living biobank of PDOs from Stage I-IV lung cancer patients (n=50). We selected enrollment of at least 50 patients so that they can be risk stratified based on lung tumor type, staging and we plan to store these PDOs in biobank for future experiments. For each patient, tumor specimens will be collected at time of their surgery. No specific therapeutic intervention or treatment is provided as part of this study.

1. Establishment and culture of PDOs from lung cancer tumor specimens. PDOs will be biobanked for future experiments.
2. Lung organoids and CTCs will also be cultured and used to study baseline tumor characteristics using histology, immunohistochemistry, atomic force measurements; as well as, oncogenic signaling pathways and proteomic profile of lung organoids and CTCs derived from lung cancer patients (n\>50).
3. Patient demographic information and data to be collected using a patient survey data sheet with treatment and survival history collected at pre-defined time period per the protocol schedule.

Eligibility criteria: Inclusion Criteria:

* Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
* Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
* Any clinical stage of lung cancer
* Adult patients ≥18 years of age
* Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history

Exclusion Criteria:

* At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

Primary outcomes:
measure: To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.
timeFrame: 10 years
Secondary outcomes:
measure: Correlation of PDO and Circulating tumor cells (CTCs)
timeFrame: 10 years
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: UT Health San Antonio, M.D. Anderson Cancer Center
state: Texas
Study officials:
affiliation: UT Health San Antonio M.D. Anderson Cancer Center
name: Josephine Taverna, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02677415: Impact of Anesthesia Type on Outcome in Patients With Acute Ischemic Stroke (AIS) Undergoing Endovascular Treatment
Official title: Impact of General vs Local Anesthesia on Neurological Function in Patients With Acute Ischemic Stroke Undergoing Endovascular Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Stroke
Keywords: Ischemic Stroke
Anesthesia
Endovascular Procedures
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2016-02-09
Enrollment: 640
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Recent observational studies have found an association between general anaesthesia and increased post-operative mortality in acute ischemic stroke patients undergoing endovascular treatment. It is unknown whether there is a causal relationship in this observation. The investigators are performing a large randomised trial of general versus local anaesthesia to definitively answer the question of whether anaesthetic type alters perioperative outcome.


Eligibility criteria: Inclusion Criteria:

* Patients with AIS scheduled to receive emergency endovascular treatment, older than 18; the onset time is within 12 hours.

Exclusion Criteria:

* Radiological ambiguity concerning infarction and vessel occlusion.
* Additional intracerebral hemorrhage.
* Posterior circulation infraction.
* Coma on admission (Glasgow coma score less than 8).
* NIHSS less than 10 or more than 35.
* Severe agitation or seizures on admission.
* Obvious loss of airway protective reflexes and/or vomiting on admission.
* Being intubated before treatment on admission.
* Known allergy to anesthetic or analgesic.

Primary outcomes:
measure: modified Rankin score
timeFrame: post-procedural 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing TianTan Hospital
Study officials:
affiliation: Department of Anesthesiology, Beijing Tiantan Hospital
name: Ruquan Han, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tosello R, Riera R, Tosello G, Clezar CN, Amorim JE, Vasconcelos V, Joao BB, Flumignan RL. Type of anaesthesia for acute ischaemic stroke endovascular treatment. Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2.
citation: Peng Y, Li Y, Jian M, Liu X, Sun J, Jia B, Dong J, Zeng M, Lin N, Zhang L, Gelb AW, Chan MT, Han R. Choice of ANesthesia for EndoVAScular Treatment of Acute Ischemic Stroke: Protocol for a randomized controlled (CANVAS) trial. Int J Stroke. 2017 Dec;12(9):991-997. doi: 10.1177/1747493017706243. Epub 2017 Apr 24.
Clinical trial NCT04948515: Gene Polymorphism of IL17 and IL 23
Official title: Association Between Gene Polymorphism of IL17 and IL 23 in Patients With COVID 19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Respiratory Infection
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-07-02
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: group 1 patients with covid 19 with severe infections admitted at ICU group 2 patients with covid 19 with nonsevere infections admitted at internal wards

Brief summary: rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Detailed description: Aim Of The Study

1. To evaluate if there is an association between the IL-17, IL-23 gene polymorphism in Patients With COVID 19 by real-time PCR
2. To measure the serum level of IL17 by ELISA in COVID 19 patients by ELISA.
3. To detect if there is an association between gene polymorphism of IL17 and IL23 and severity of a condition in patients with COVID 19 Study design: a cross-sectional study.

The blood samples will be collected from patient records in COVID19 isolation hospitals in sohag governorate and isolation department in sohag university hospitals.

Eligibility criteria: Inclusion Criteria:

* Patients with Covid19 positive PCR

Exclusion Criteria:

* Patients with Covid19 clinical criteria not confirmed by PCR

Primary outcomes:
measure: genotyping of IL 17
timeFrame: 3-6-2021 to 30-8-2021
measure: genotyping of IL 23
timeFrame: 3-6-2021 to 30-8-2021
measure: estimation of serum level of IL 17
timeFrame: 3-6-2021 to 30-8-2021
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
affiliation: Sohag University
name: N S shafik, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00527215: Phase 2 Study of Darbepoetin Alfa Extended Dosing
Official title: A Study of Darbepoetin Alfa Administered Once Every Four Weeks in Chronic Renal Insufficiency (CRI) Subjects With Anemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pre-Dialysis
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2007-09-10
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Multicenter, open label single arm study in which 140 subjects with CRI who are currently receiving SC darbepoetin alfa once every other week will receive darbepoetin alfa once every 4 weeks for 24 weeks. Upon enrollment into this study, subjects will receive darbepoetin alfa once every 4 weeks for 24 weeks. The initial dose will be equivalent to the subject's total dose in the month preceding enrollment. Doses may be titrated to maintain the Hb concentration in the target range.


Eligibility criteria: Inclusion Criteria:

* Greater than or equal to 18 years of age
* CRI with a creatinine clearance of greater than 15 but less than 40 mL/min
* Stable once every other week darbepoetin alfa SC for at least 6 weeks
* Hb values during screening / baseline of 10.0 - 12.0 g/dL
* Serum B12 and folate levels above the lower limit of normal and iron replete

Exclusion Criteria:

* Receiving renal replacement therapy
* Uncontrolled hypertension
* Hyperparathyroidism
* Major surgery, active inflammatory disease, receiving antibiotics, HIV-positive
* Current malignancy
* Pregnant or breast-feeding

Primary outcomes:
measure: To assess the proportion of CRI subjects maintaining a target hemoglobin (Hb) range of 10.0 to 12.0 g/dL when administered subcutaneous (SC) darbepoetin alfa once every 4 weeks
timeFrame: Study weeks 21 - 29
Secondary outcomes:
measure: To assess the safety, toleratbility, and pharmacokinetic (PK) profile of darbepoetin alfa when administered once every 4 weeks.
timeFrame: Entire study
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
citation: Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005 May;63(5):327-34. doi: 10.5414/cnp63327.
citation: Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc. 2007 Feb;8(2):83-90. doi: 10.1016/j.jamda.2006.07.007. Epub 2006 Sep 29.
Clinical trial NCT05360615: The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Official title: The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Empagliflozin in Post AKI Stage 2-3
Keywords: Empagliflozin
AKI
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2022-05-04
Enrollment: 147
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.


Eligibility criteria: Inclusion Criteria:

* post AKI stage 2-3
* CrCl \> 20

Exclusion Criteria:

* pregnancy
* post kidney transplant
* previous use of SGLT2 Inhibitors
* history of ketoacidosis

Primary outcomes:
measure: MAKE365
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Nonthaburi
country: Thailand
facility: Central Chest Institute of Thailand
state: Mueang Nonthaburi District
Study officials:
affiliation: Chulalongkorn University
name: Nattachai Srisawat
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02109315: Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
Official title: Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Type 1 Diabetes Mellitus
Lead sponsor: Fundacion Clinic per a la Recerca Biomédica
Sponsor class: OTHER
First posted: 2014-04-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function

Detailed description: To investigate the effect of antioxidants (Vitamin C) on the vascular damage induced hypoglycemia in patients with type 1 diabetes. The vascular injury was evaluated in the same way as main objective. Checking the existence of a peripheral response to the action of GLP-1 due to oxidative stress.

Eligibility criteria: Inclusion Criteria:

* Informed and signed consent obtained before any trial-related activity . ( Trial-related activities are those procedures that were not performed during routine medical examination of the patient) .
* Diagnosis of type 1 diabetes.
* Patients who do not have autonomic dysfunction , defined by ( 1).
* Patients not showing episodes of hypoglycemia unawareness based on the methods of Gold et al (2) .
* Patients without microvascular complications of diabetes.
* Patients without macrovascular complications of diabetes.
* Patients treated with multiple daily injections of insulin.
* No smoking .
* They should have a complete blood count, lipid profile, liver profile , renal profile and plasma electrolyte levels within normal values .
* No subject must have a history of hypertension or taking medication for high blood pressure .
* No subject should be taking medications known to affect the neuroendocrine responses to hypoglycemia or anti inflammatory

Exclusion Criteria:

* Known or suspected hypersensitivity to study some related products.
* Fertile women, lactating or pregnant, intend to become pregnant or who are not using adequate contraception, or men who have sexually active and are not sterilized surgically, those whose partners are not using a method adequate contraception.
* Clinical diagnosis of Type 2 Diabetes.

Primary outcomes:
measure: Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.
timeFrame: 8 weeks
Secondary outcomes:
measure: Oxidative stress markers
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clinic i Provincial de Barcelona
Study officials:
affiliation: Hospital clínic i provincial de Barcelona
name: Antonio Ceriello A Ceriello, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03354715: Patient Satisfaction and Retention of Upper Complete Denture Base Using Rapid Prototyping Versus a Conventional One
Official title: Patient Satisfaction and Retention of Upper Complete Denture Base Using Rapid Prototyping Versus a Conventional One: Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Complete Denture
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-11-28
Enrollment: 16
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Comparing patient satisfaction and retention of upper complete denture fabricated using two different denture base materials, the first fabricated using rapid prototyping method while the second is following conventional methods.

Detailed description: Searching for other materials or other fabrication technologies has been one of the goals to help to re-innovate the fabrication of complete dentures , which would greatly influence completely edentulous Patient satisfaction. The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.

SLA has been used in dental fields like maxillofacial prosthesis , wax pattern fabrication for crown bridge , removable partial denture 19, but still complete denture was reported in a very few reports indicating that RP is not yet successfully applied in Complete denture manufacturing 19-21A randomised trial is therefore needed to asses accurately wether the introduction of rapid prototyping in complete denture fabrication is successful or not in comparison to the conventional technique and to discover the possible challenges in this recent technique and the ways to overcome it.

Retention of complete dentures and patient satisfaction has been reported in many studies22-26. Patients have showed a higher satisfaction, as retention of both maxillary and mandibular complete dentures increased.

Eligibility criteria: Inclusion Criteria:

1. Age ranging from 40-70 years.
2. Patients who can understand and respond to a written questionnaire in Arabic.
3. Cooperative patients

Exclusion Criteria:

1. Pathological changes of residual ridges.
2. Patients with debilitating systemic diseases.
3. Patients with xerostomia.
4. Patients with flabby and flat ridges.
5. Patients with allergy to acrylic resin
6. Patient with sever undercuts, or irregular bony exostosis

Primary outcomes:
measure: Patient Satisfaction
timeFrame: 3 month
Secondary outcomes:
measure: Retention
timeFrame: 3 month
Other outcomes:
Locations:
city: CAiro
country: Egypt
facility: Faculty of Dentistry
Study officials:
References: